J. Melo

发表

Roots of clinical resistance to STI-571 cancer therapy.

C. Barthe, P. Cony-Makhoul, J. Melo, 2001, Science.

Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-γ1-driven activation of mTOR/p70S6-kinase pathway

J. Melo, T. Brümmendorf, J. Duyster, 2010, Oncogene.

Cancer stem cell definitions and terminology: the devil is in the details

H. Johnsen, G. Stassi, R. Maria, 2012, Nature Reviews Cancer.

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.

J. Melo, J V Melo, 1996, Blood.

BCR-ABL gene variants.

J. Melo, 1997, Bailliere's clinical haematology.

The molecular biology of chronic myeloid leukemia.

J. Melo, M. Deininger, J. Goldman, 2000, Blood.

Chronic myeloid leukaemia as a model of disease evolution in human cancer

Junia V. Melo, J. Melo, D. Barnes, 2007, Nature Reviews Cancer.

Chronic Myeloid Leukaemia

J. Melo, D. A. Casolari, 2015 .

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

J. Melo, J. Goldman, 2008, Acta Haematologica.

Chronic myeloid leukemia – some topical issues

O. Hantschel, J. Melo, H. Kantarjian, 2007, Leukemia.

Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.

J. Melo, S. Basu, K. Igarashi, 2007, Blood.

Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.

J. Melo, H. Kantarjian, M. Talpaz, 2000, Hematology. American Society of Hematology. Education Program.

Mechanisms of resistance to BCR–ABL kinase inhibitors

J. Melo, J. Diamond, 2011, Leukemia & lymphoma.

P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?

J. Melo, D. Galton, J. Goldman, 1994, Leukemia.

p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.

J. Melo, J. Goldman, N. Cross, 1996, Blood.

reduced antigen processing, and impaired migration Dendritic cells from CML patients have altered actin organization,

J. Melo, R. Lechler, A. Ridley, 2013 .

Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.

J. Melo, R. Lechler, A. Ridley, 2003, Blood.

Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.

E. Lam, G. Peters, J. Melo, 2001, Cancer research.

Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia

J. Melo, D. Barnes, B. Schultheis, 2005, Oncogene.

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

J. Melo, M. Deininger, 2004, Hematology/oncology clinics of North America.

Inviting leukemic cells to waltz with the devil

J. Melo, 2001, Nature Medicine.

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia

S. Lewis, J. Melo, J. England, 1986, British journal of haematology.

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia

J. Melo, D. Catovsky, D. Galton, 1986, British journal of haematology.

Markers of differentiated B cell leukaemia: CD22 antibodies and FMC7 react with different molecules.

J. Melo, D. Catovsky, H. Zola, 1987, Disease markers.

prognosis of chronic myeloid leukemia The polycomb group BMI-1 gene is a molecular marker for predicting

J. Melo, M. Mohty, J. Apperley, 2013 .

Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies.

J. Melo, A. Tipping, 2003, Seminars in hematology.

The molecular biology of chronic myeloid leukaemia.

J. Melo, 1996, Leukemia.

Chronic myeloid leukemia: the possibility of a cure

J. Melo, M. Sobrinho-Simões, D. Ross, 2013 .

Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

J. Melo, D. Ross, 2011, Hematology. American Society of Hematology. Education Program.

Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.

J. Melo, C. Chuah, 2008, Hematology. American Society of Hematology. Education Program.

Upregulation of the TGFβ signalling pathway by Bcr‐Abl: Implications for haemopoietic cell growth and chronic myeloid leukaemia

J. Melo, A. Chantry, V. Frost, 2007 .

Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.

J. Melo, S. Reid, J. Goldman, 2003, Blood.

SCH66336 Overcoming STI571 resistance with the farnesyl transferase inhibitor

G. Daley, J. Melo, F. Mahon, 2013 .

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells

J. Melo, A. Fields, S. Koschmieder, 2012, PloS one.

Pathophysiology of Chronic Myeloid Leukemia

J. Melo, A. Yong, 2011 .

The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib

J. Melo, D. Marin, J. Goldman, 2009, Haematologica.

Novel compounds with antiproliferative activity against imatinib-resistant cell lines

J. Melo, D. Kufe, A. Deisseroth, 2007, Molecular Cancer Therapeutics.

Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines

J. Melo, D. Barnes, É. Moravcsik, 2007, Leukemia.

Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.

J. Melo, F. Mahon, J. Apperley, 2005, Blood.

Overproduction of BCR‐ABL induces apoptosis in imatinib mesylate‐resistant cell lines

J. Melo, J. Reiffers, V. Praloran, 2005, Cancer.

Molecular profiling of CD34+ cells identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival in CML patients (*)

J. Melo, J. Goldman, J. Apperley, 2005 .

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.

J. Melo, B. Druker, A. Corbin, 2004, Blood.

Overcoming STI 571 resistance with the farnesyl transferase inhibitor SCH 66336

G. Daley, J. Melo, F. Mahon, 2002 .

Restoration of sensitivity to STI 571 in STI 571-resistant chronic myeloid leukemia cells

J. Melo, J. Goldman, F. Mahon, 2001 .

Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia

J. Melo, T. Hughes, D. Ross, 2014 .

Handbook of Chronic Myeloid Leukemia

J. Melo, T. Hughes, D. Ross, 2014 .

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

J. Melo, D. Marin, J. Goldman, 2006, Leukemia.

Resistance to imatinib mesylate in chronic myeloid leukaemia.

J. Melo, C. Chuah, 2007, Cancer letters.

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells

J. Melo, B. Druker, A. Corbin, 2005, Leukemia.

Chronic myeloid leukemia.

J. Melo, T. Hughes, J. Apperley, 2003, Hematology. American Society of Hematology. Education Program.

Imatinib: can one outwit chronic myeloid leukemia?

J. Melo, L. Luzzatto, F. Frassoni, 2002, Haematologica.

Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene

J. Melo, M. Deininger, J. Goldman, 2001, Genes, chromosomes & cancer.

Biological Markers in Lymphoproliferative Disorders

J. Melo, D. Catovsky, E. Matutes, 1985 .

The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.

J. Melo, J. Goldman, N. Cross, 1993, Blood.

The ABL-BCR Fusion Gene Is Expressed in Chronic Myeloid Leukemia

J. Melo, J. Goldman, N. Cross, 1993 .

The Biology and Pathogenesis of Chronic Myeloid Leukemia

J. Melo, Bradley Chereda, 2016 .

Natural course and biology of CML

J. Melo, Bradley Chereda, 2015, Annals of Hematology.

Proteasome proteolytic profile is linked to Bcr-Abl expression.

J. Melo, H. Ovaa, M. McMullin, 2009, Experimental hematology.

Establishment and characterization of three new malignant lymphoid cell lines

L. Kearney, J. Melo, D. Catovsky, 1987, International journal of cancer.

Analysis of genomic breakpoints in p190 and p210 BCR–ABL indicate distinct mechanisms of formation

B. Nadel, R. Yeh, J. Melo, 2010, Leukemia.

Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models

J. Melo, T. Holyoake, M. Aujay, 2014, Oncogenesis.

Antileukemic Activity of Lysophosphatidic Acid Acyltransferase-β Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib

J. Melo, B. Druker, M. Deininger, 2006, Clinical Cancer Research.

Cross‐resistance of imatinib mesylate and 17‐aag in imatinib‐resistant cells that overexpress bcr‐abl

J. Melo, W. Zeller, J. Topaly, 2003, British journal of haematology.

Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.

J. Melo, J. Goldman, S. O’Brien, 1994, Leukemia.

BCR‐ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia

J. Melo, T. Holyoake, G. Strathdee, 2012, British journal of haematology.

High-Dose Ionizing Radiation Selective Induction of Leukemia-associated Fusion Genes by Updated

John, Shikha, J. Melo, 2006 .

Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation.

J. Melo, M. Deininger, S. Bose, 1998, Cancer research.

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications

J. Melo, L. To, Sharad Kumar, 2008, Clinical Cancer Research.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

J. Melo, A. Schwarer, J. Seymour, 2013, Blood.

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

J. Melo, R. D'Andrea, Angel F. Lopez, 2010, Leukemia.

Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells

J. Melo, D. White, T. Hughes, 2009, Leukemia.

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib

J. Melo, C. Chuah, 2009, OncoTargets and therapy.

OTT-3971-Targeted treatment of imatinib-resistant chronic my

J. Melo, C. Chuah, 2009 .

Prolymphocytic leukemia of B cell type: rearranged immunoglobulin (Ig) genes with defective Ig production.

J. Melo, D. Catovsky, L. Luzzatto, 1985, Blood.

Management of Patients with Chronic Myeloid Leukemia

J. Melo, T. Hughes, D. Ross, 2014 .

Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms.

J. Melo, E. Robinet, P. Tiberghien, 2002, Blood.

BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.

E. Lam, J. Melo, C. Rivas, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.

J. Radich, J. Melo, G. Martinelli, 2011, Blood.

A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.

J. Melo, A. Reiter, N. Cross, 1996, Blood.

BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.

J. Melo, J. Goldman, J. Diamond, 1995, Blood.

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.

J. Melo, Y. Hayashi, H. Hirai, 2011, Cancer letters.

Myeloid Leukemia Development of Resistance to Imatinib Mesylate in Chronic Bcr-Abl Expression Levels Determine the Rate of Updated

J. Melo, L. Pattacini, J. Goldman, 2005 .

Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.

J. Melo, J. Goldman, N. Cross, 1996, Leukemia.

Monitoring Response to Treatment

J. Melo, T. Hughes, D. Ross, 2014 .

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

J. Melo, A. Schwarer, J. Seymour, 2010, Leukemia.

Reply to ‘Does post-transplant treatment with imatinib mesylate inhibit graft-versus-leukemia?’ by Chunduri et al

J. Melo, F. Dazzi, K. Cwynarski, 2005, Leukemia.

BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.

J. Melo, M. Deininger, J. Goldman, 2000, Cancer research.

Myeloid Leukemia of Multiple Genes Implicated in the Pathogenesis of Chronic Tyrosine Kinase Activity Regulates the Expression BCR-ABL Updated

J. Melo, M. Deininger, J. Goldman, 2000 .

Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens.

J. Melo, D. Catovsky, U. Hegde, 1987, Journal of clinical pathology.

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

J. Melo, L. To, C. Hui, 2013 .

Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia.

J. Melo, D. Catovsky, M. Brozovīc, 1984, Seminars in oncology.

Do we have to kill the last CML cell?

J. Melo, D. Ross, T. P. Hughes, 2011, Leukemia.

Imatinib and ABCG2: who controls whom?

J. Melo, 2006 .

Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia

J. Melo, G. Stefanzl, T. Rülicke, 2018, Neoplasia.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells

J. Melo, G. Stefanzl, U. Jäger, 2017, Oncotarget.

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia

H. Maeda, J. Melo, G. Stefanzl, 2014, Oncotarget.

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells

J. Melo, F. Heidel, D. Lipka, 2013, Leukemia.

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells

J. Melo, O. Cuvillier, B. Malavaud, 2008, Leukemia.

Splenic B cell lymphoma with "villous" lymphocytes in the peripheral blood: a disorder distinct from hairy cell leukemia.

J. Melo, D. Catovsky, D. Robinson, 1987, Leukemia.

Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.

J. Melo, J. Goldman, S. Dhut, 1993, Blood.

An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.

J. Melo, J. Goldman, N. Cross, 1994, Leukemia.

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

J. Melo, D. White, T. Hughes, 2010, Leukemia.

Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model.

J. Melo, R. Gosden, B. Schultheis, 2012, Leukemia research.

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.

T. Lister, T. A. Lister, J. Melo, 2006, Leukemia research.

The 14q+ marker in hairy cell leukaemia. A cytogenetic study of 15 cases.

J. Melo, D. Catovsky, S. Pittman, 1986, Leukemia research.

Morphology and immunology of circulating cells in leukaemic phase of follicular lymphoma.

J. Melo, D. Catovsky, D. Galton, 1988, Journal of clinical pathology.

Do we have to kill the last CML cell?

J. Melo, D. Ross, T. P. Hughes, 2011, Leukemia.

Two new cell lines from B‐prolymphocytic leukaemia: Characterization by morphology, immunological markers, karyotype and Ig gene rearrangement

J. Melo, D. Catovsky, L. Luzzatto, 1986, International journal of cancer.

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

J. Melo, W. Bornmann, D. Veach, 2003, Leukemia.

Intracytoplasmic inclusions in B prolymphocytic leukaemia: ultrastructural, cytochemical, and immunological studies.

J. Melo, D. Catovsky, S. Schey, 1985, Journal of clinical pathology.

leukemia cells Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid

J. Melo, J. Goldman, F. Mahon, 2013 .

Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells

J. Melo, R. Hehlmann, A. Hochhaus, 2007 .

Wrapping BCR-ABL: it's in the bag.

J. Melo, D. Hewett, 2010, Blood.

Clonal and lineage analysis of somatic DNMT3A and JAK2 mutations in a chronic phase polycythemia vera patient

J. Melo, R. D'Andrea, I. Lewis, 2012, British journal of haematology.

Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.

J. Melo, P. Tiberghien, C. Ferrand, 2001, Blood.

Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia.

J. Melo, J. Griffin, R. Stone, 2015, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1

J. Melo, L. Zhang, A. Jones, 2009, Leukemia.

Chronic lymphocytic leukemia and prolymphocytic leukemia: a clinicopathological reappraisal.

J. Melo, D. Catovsky, D. Galton, 1987, Blood cells.

Reactivity of the monoclonal antibody RFB1 in chronic B-cell leukaemias.

J. Melo, D. Catovsky, M. Bodger, 2009, Scandinavian journal of haematology.

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

J. Melo, J. Goldman, J. Apperley, 2006, Blood.

The leukocyte-common antigen (CD45) complex and B-lymphocyte activation.

J. Melo, J. Skinner, H. Zola, 1990, Human immunology.

Lack of correlation between ABL‐BCR expression and response to interferon‐α in chronic myeloid leukaemia

J. Melo, J. Goldman, A. Hochhaus, 1996 .

Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.

J. Melo, A. Hochhaus, J. Goldman, 1996, British journal of haematology.

B Prolymphocytic Leukemia Cell Lines: Phenotype and Response to B Cell Differentiation Factor

J. Melo, D. Catovsky, H. Zola, 1988, Pathology.

Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts.

J. Melo, J. Goldman, N. Kent, 1994, Blood.

Neoplastic x and λ cells in a B‐PLL with chromosome translocations of both light chain gene regions

J. Melo, D. Catovsky, L. Foroni, 1984 .

Neoplastic kappa and lambda cells in a B-PLL with chromosome translocations of both light chain gene regions.

J. Melo, D. Catovsky, L. Foroni, 1984, International journal of cancer.

The human leucocyte P30 antigen: properties and assessment of value as a clonal marker.

J. Melo, A. Morley, D. Catovsky, 2008, Tissue antigens.

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.

B. Bain, J. Melo, D. Marin, 2002, The New England journal of medicine.

Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T lymphoma

J. Melo, C. Rivas, E. Simpson, 2000, Cancer Gene Therapy.

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia

J. Melo, D. Catovsky, D Catovsky, 1986, British journal of haematology.

Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia

J. Melo, D. J. Barnes, 2002, Acta Haematologica.

Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.

J. Melo, S. O’Brien, R. Capdeville, 2002, Blood.

Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease

J. Melo, C. Yoshida, 2004, International journal of hematology.

Chronic Myeloid Leukemia: Biology of Advanced Phase

J. Melo, D. J. Barnes, 2007 .

In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.

J. Melo, N. Cross, M. Sobrinho-Simões, 2010, Blood.

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

J. Melo, F. Moreau-Gaudry, J. Goldman, 2003, Blood.

Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

J. Melo, G. Lombardi, F. Dazzi, 2004, Leukemia.

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

J. Melo, M. Deininger, J. Goldman, 2000, Blood.

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

J. Melo, N. Lydon, M. Deininger, 1997, Blood.

Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia

J. Melo, David D. F. Ma, S. Carlin, 2016, Leukemia & lymphoma.

Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5

J. Melo, K. Igarashi, M. Makri, 2013, Leukemia.

The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.

J. Melo, M. Deininger, J. Goldman, 1998, Blood.

with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34

Y. Turpaz, C. Harrington, S. McWeeney, 2011 .

Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.

J. Melo, F. Catanzano, F. Salvatore, 2010, Biochimica et biophysica acta.

Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming

M. Carroll, J. Melo, C. Thompson, 2010, Oncogene.

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Beth Wilmot, Shannon K McWeeney, Jennifer L. Snead, 2010, Blood.

Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia

J. Melo, B. Turcq, F. Moreau-Gaudry, 2007, Leukemia.

Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.

J. Melo, M. Deininger, J. Goldman, 2003, Experimental hematology.

Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.

J. Melo, C. Walsh, S. Ong, 2003, Cancer research.

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

G. Daley, J. Melo, F. Mahon, 2002, Blood.

Management of chronic myeloid leukemia: targets for molecular therapy.

J. Melo, D. J. Barnes, 2003, Seminars in hematology.

Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis

Robert Brown, J. Melo, T. Holyoake, 2007, Clinical Cancer Research.

leukemia cell line models MDR1 gene overexpression confers resistance to imatinib mesylate in

J. Melo, F. Moreau-Gaudry, J. Goldman, 2013 .

Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.

J. Melo, J. Goldman, F. Mahon, 2001, Blood.

Chronic myeloid leukemia--advances in biology and new approaches to treatment.

J. Melo, J. Goldman, 2003, The New England journal of medicine.

The Biology and Pathogenesis of Chronic Myeloid Leukaemia

J. Melo, Bradley Chereda, N. Shanmuganathan, 2021, Hematologic Malignancies.

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia.

J. Melo, M. Mohty, J. Apperley, 2007, Blood.

The polycomb group BMI 1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia

Junia V. Melo, Jane F. Apperley, J. Melo, 2007 .

ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia.

J. Melo, N. Cross, R. Hehlmann, 2001, Blood.

CD40 and B-cell receptor signalling induce MAPK family members that can either induce or repress Bcl-6 expression.

E. Lam, K. Naresh, J. Melo, 2009, Molecular immunology.

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

J. Melo, J. Goldman, 2001, The New England journal of medicine.

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.

J. Melo, L. Pattacini, J. Goldman, 2005, Cancer research.

Abnormally Small BCR-ABL Transcripts in CML Patients before and during Imatinib Treatment.

J. Melo, D. Marin, S. Kamel‐Reid, 2006 .

Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH‐296

J. Melo, J. Goldman, A. Miller, 1999, British journal of haematology.

Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C.

J. Melo, L. Álvarez-Vallina, J. G. Viniegra, 2005, The Biochemical journal.

Comparative gene expression profile of p185(Bcr-Abl) versus p210(Bcr-Abl) expressing cells.

J. Melo, A. Tipping, 2004, Leukemia research.

The impact of gene profiling in chronic myeloid leukaemia.

J. Melo, A. Yong, 2009, Best practice & research. Clinical haematology.

BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis

J. Melo, R. Clark, L. Wang, 2003, Leukemia.

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

J. Melo, B. Calabretta, R. Clark, 2017, Journal of the National Cancer Institute.

Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia

J. Melo, G. Nteliopoulos, P. Luong, 2010, Cell Death and Disease.

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.

J. Melo, G. Hawson, P. Koduru, 2001, Blood.

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function

T. Fioretos, J. Melo, M. Ehinger, 2011, Leukemia.

BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry

J. Melo, M. Copland, A. Hamilton, 2006, Leukemia.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Francisco Cervantes, Ryuzo Ohno, Richard E. Clark, 2013, Blood.

Primary plasma cell leukaemia: immunological and ultrastructural studies in 6 cases.

J. Melo, J. Katzmann, S. Ball, 2009, Scandinavian journal of haematology.

Chromosome abnormalities at 11q13 in B cell tumours

J. Melo, D. Catovsky, T. Rabbitts, 1988 .

Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.

J. Melo, R. Kerbel, E. Buchdunger, 2002, Molecular cancer research : MCR.

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

J. Melo, T. Hughes, S. Branford, 2009, Blood.

Chronic myeloid leukemia: the basis of treatment for tomorrow

J. Melo, G. Martinelli, J. Goldman, 2011, Haematologica.

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

James D. Griffin, Andrew L. Kung, Taebo Sim, 2010, Blood.

A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL

G. Superti-Furga, K. Bennett, J. Colinge, 2013, PloS one.

ORIGINAL ARTICLE BCR-ABL activity and its response to drugs can be determined in CD34 þ CML stem cells by CrkL phosphorylation status using flow cytometry

J. Melo, M. Copland, A. Hamilton, 2006 .

The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia

W. Gregory, J. Melo, D. Catovsky, 1987, British journal of haematology.

Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.

J. Melo, G. McArthur, J. Goldman, 2007, Blood.

Splenectomy in advanced chronic lymphocytic leukaemia.

J. Melo, D. Catovsky, G. Gallhofer, 1987, Acta haematologica.

Production of P‐glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first‐line chemotherapy in advanced breast cancer

J. Foekens, A. Sieuwerts, S. Raguz, 2007, International journal of cancer.

Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia.

J. Melo, D. Catovsky, S. Pittman, 1987, Hematologic pathology.

Ex vivo expansion and characterisation of CD34+ cells derived from chronic myeloid leukaemia bone marrow and peripheral blood, and from normal bone marrowand mobilised peripheral blood

J. Melo, J. Apperley, M. Garin, 2000, European journal of haematology.

Lack of imprinting of the ABL gene

J. Melo, J. Goldman, J. Diamond, 1994, Nature Genetics.

Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.

J. Melo, M. Mohty, J. Goldman, 2008, Blood.

Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG

S Fruehauf, A. Jauch, J. Melo, 2005, Leukemia.

The susceptibility of Philadelphia chromosome positive cells to FAS‐mediated apoptosis is not linked to the tyrosine kinase activity of BCR‐ABL

J. Melo, J. Goldman, M. Deininger, 1998, British journal of haematology.

Different reactivity of monoclonal antibodies against common acute lymphoblastic leukaemia antigen (CD10).

J. Melo, D. Catovsky, S. Haralambidou, 1987, Journal of clinical pathology.

The membrane phenotype of hairy cell leukemia: a study with monoclonal antibodies.

J. Melo, D. Catovsky, J. S. San Miguel, 1984, Seminars in oncology.

Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin

J. Melo, S. Branford, J V Melo, 2009, Leukemia.

Response of STI571-resistant cells to other chemotherapeutic drugs and signal transduction inhibitors.

J. Melo, J. Goldman, F. Mahon, 2000 .

Monitoring CML after nonmyeloablative transplantations: how negative is negative?

J. Melo, J. Goldman, J. Kaeda, 2003, Blood.

Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL–Positive Cells

J. Klawitter, L. Boros, J. Melo, 2009, Clinical Cancer Research.

Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.

J. Melo, J. Goldman, 1992, Leukemia.

Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.

J. Melo, J. Goldman, A. Hochhaus, 2002, Blood.

Acquired resistance to imatinib mesylate: selection for pre-existing mutant cells.

J. Melo, L. Luzzatto, 2002, Blood.

Modulation of the p 38 MAPK ( mitogen-activated protein kinase ) pathway through Bcr / Abl : implications in the cellular response to AraC

J. Melo, L. Álvarez-Vallina, J. G. Viniegra, 2005 .

RUNX1 mutations are rare in chronic phase polycythaemia vera

J. Melo, I. Lewis, H. Scott, 2011, British journal of haematology.

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia

Iris Z. Uras, N. Gray, J. Zuber, 2019, Nature Communications.

BCR‐ABL‐positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions

J. Melo, J. Goldman, A. Chase, 1996, British journal of haematology.

In Contrast to Imatinib, OCT-1 Mediated Influx Has Minimal Impact on Cellular Uptake of Dasatinib in CML Patients at Diagnosis.

J. Melo, L. To, D. White, 2007 .

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

J. Klawitter, J. Klawitter, U. Christians, 2009, British journal of pharmacology.

The establishment of cell lines from chronic B cell leukaemias: evidence of leukaemic origin by karyotypic abnormalities and Ig gene rearrangement.

J. Melo, D. Catovsky, L. Luzzatto, 1988, Clinical and experimental immunology.

Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571

C. Barthe, P. Cony-Makhoul, J. Melo, 2002, British journal of haematology.

One Year into the COVID-19 Pandemic

J. Melo, M. Mohty, 2021, Clinical hematology international.

Antigenic expression of B-cell chronic lymphocytic leukemic cell lines.

G. Marti, J. Melo, M. Crescenzi, 1992, Leukemia & lymphoma.

The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia

J. Burthem, J. Melo, T. Holyoake, 2007, Molecular biotechnology.

Advances in Brief Bcr-Abl Kinase Modulates the Translation Regulators Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Leukemia Cells via the Mammalian Target of Rapamycin 1

J. Melo, C. Walsh, S. Ong, 2003 .

Leukemia Cells via the Mammalian Target of Rapamycin Ribosomal Protein S 6 and 4 EBP 1 in Chronic Myelogenous Bcr-Abl Kinase Modulates the Translation Regulators

J. Melo, C. Walsh, S. Ong, 2003 .

RESEARCH PAPER Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells

J. Klawitter, J. Klawitter, U. Christians, 2009 .

Oncotargets and Therapy Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Targeted Treatment of Imatinib-resistant Chronic Myeloid Leukemia: Focus on Dasatinib

J. Melo, C. Chuah, 2022 .

Nuclear positioning of the BACH2 gene in BCR‐ABL positive leukemic cells

J. Melo, K. Igarashi, Masao Kobayashi, 2007, Genes, chromosomes & cancer.

Inactivation of HOXAGenes by Hypermethylation in Myeloid and LymphoidMalignancy is Frequent and Associated with Poor Prognosis

Robert Brown, J. Melo, T. Holyoake, 2007 .

Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients

T. Speed, J. Melo, A. Morley, 2013, Leukemia.

Running head: Imatinib Cessation After Stable UMRD in CML

J. Melo, A. Schwarer, J. Seymour, 2017 .

How cured are CML patients in complete molecular remission (CMR) after stem cell transplantation or imatinib

J. Melo, N. Cross, J. Score, 2007 .

Intracellular Retention of ABL Kinase Inhibitors Determines Commitment to Apoptosis in CML Cells

J. Melo, C. Müller-Tidow, F. Heidel, 2012 .

BMS-214662 Eliminates CML Stem Cells and Is Active Against Blast Crisis CML and Cells Expressing BCR-ABL Kinase Mutations.

J. Melo, M. Copland, A. Hamilton, 2006 .

Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia blast crisis

J. Melo, J. Reiffers, P. Berthaud, 2000 .

BCR-ABL in Chronic Myelogenous Leukemia – How Does It Work?

J. Melo, J. Goldman, 2008, Acta Haematologica.

Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.

J. Melo, C. Chuah, 2008, Hematology. American Society of Hematology. Education Program.

J. Melo, C. Chuah, 2022 .